EichorEICHOR
Study identifier: NCT07746479 Synced from ClinicalTrials.gov · August 05, 2026
● Completed

A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )

Condition: Psoriasis  ·  Sponsor: Livzon Pharmaceutical Group Inc.

PhasePhase 3
Planned participants244
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is a Multicenter, Open-Label, Single-Arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of LZM012 Injection in Patients With Moderate to Severe Plaque Psoriasis.

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Dermatology HospitalShanghai, China

Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →